CA COST Action CA16225
Realising the therapeutic potential of novel cardioprotective therapies
Action website: http://www.cost.eu/COST_Actions/ca/CA16225
Project Official Website: http://www.cardioprotection.eu/
Members of Committee: Lana Nežić, Jelena Jovanić* and Vesna Vujić-Aleksić, Faculty of Medicine, University of Banja Luka; *University Clinical Center Republic of Srpska, Banja Luka;
This EU-CARDIOPROTECTION COST ACTION will address this challenge by setting up a pan-European Research Network of leading experts in cardioprotection, to jointly develop innovative strategies for translating novel cardioprotective therapies into the clinical setting for patient benefit. This will be achieved through 4 main objectives each linked to a WORKING GROUP [WG]:(1) To use innovative strategies to discover novel targets for cardioprotection (WG1: NEW TARGETS). (2) To investigate the effects of combination therapy directed to multiple targets as an innovative cardioprotective strategy (WG2: COMBINATION THERAPY). (3) To use more clinically relevant animal models for testing novel cardioprotective therapies taking into account the confounding effects of co-morbidities and co-medication (WG3: CONFOUNDERS). (4) To set up a European network of research centers (European Cardioprotection Consortium, ECC) for (a) Multi-center preclinical testing of novel cardioprotective therapies using small/large animal models of acute myocardial IRI; and (b) Proof-of-concept clinical testing of novel cardioprotective therapies in AMI patients (WG4:CONSORTIUM). The EU-CARDIOPROTECTION COST ACTION aims to improve the translation of novel cardioprotective therapies for patient benefit.